Race Oncology Ltd has released a press release.
Positive Pre-IND Guidance from FDA on Zantrene
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Response to ASX Price Query
- Race Develops Improved IV Formulation of Zantrene
- Race Initiates New Drug Discovery Program
- Race Oncology: Update - Notification of buy-back - RAC
- Race Oncology: RAC Quarterly Investor Presentation
Later from Racura Oncology
- Race Appoints Damian Clarke-Bruce as CEO & Managing Director
- Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
- Race supports Study of Extramedullary AML
- Race Receives Cardioprotection Ethics Trial Approval
- New Collaboration to Understand Zantrene Cardioprotection
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology